Scarica l'app Stockscreener
0.7321
2.39%
-0.0179
Pre-mercato:
.70
-0.0321
-4.38%
Metavia Inc Borsa (MTVA) Ultime notizie
MetaVia to Present at the Life Sciences Virtual Investor Forum June 12th - GlobeNewswire
MetaVia Announces Poster Presentation on DA-1241 at the ADA's 85th Scientific Sessions - Eastern Progress
MetaVia Sees Obesity Opportunities Despite Challenging US Market - insights.citeline.com
MTVA stock touches 52-week low at $0.64 amid market challenges By Investing.com - Investing.com South Africa
MetaVia Inc. receives Nasdaq non-compliance notice - Investing.com Australia
MetaVia Faces Nasdaq Delisting Notice for Low Stock Price - TipRanks
MTVA stock touches 52-week low at $0.64 amid market challenges - Investing.com Nigeria
MetaVia Reports Progress in Obesity and MASH Treatments - TipRanks
MTVA: Additional Positive Topline Results for DA-1726 in Phase 1 MAD Study… - Zacks Small Cap Research
MetaVia Updates Corporate Presentation on DA-1726 Progress - TipRanks
Presenting on Emerging Growth Conference 82 Day 2 on May 22; Register to live stream - GlobeNewswire
Major Investment Alert: DONG-A ST CO., LTD Boosts Stake in MetaVia! - TipRanks
MetaVia (NASDAQ:MTVA) Price Target Lowered to $3.00 at Maxim Group - Defense World
Maxim Group Lowers MetaVia (MTVA) Price Target to $3.00 | MTVA S - GuruFocus
MetaVia price target lowered to $3 from $6 at Maxim - TipRanks
MetaVia (MTVA) Price Target Cut as Analyst Highlights Future Pro - GuruFocus
MetaVia Inc reports results for the quarter ended March 31Earnings Summary - TradingView
MetaVia Reports First Quarter 2025 Financial Results and Provides Corporate Update - WV News
MetaVia Completes $10 Million Private Placement - TipRanks
MetaVia launches $10M private placement - MSN
MetaVia secures $10 million in private placement - Investing.com
MetaVia (MTVA) to Raise $10M Through Private Placement | MTVA St - GuruFocus
MetaVia secures $10 million in private placement By Investing.com - Investing.com South Africa
MetaVia announces $10M private placement - TipRanks
MetaVia Inc. announced that it expects to receive $9.995395 million in funding - marketscreener.com
Metavia Announces $10 Million Private Placement Priced At-The-Market Under Nasdaq Rules - marketscreener.com
MetaVia Announces $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules - Eastern Progress
MetaVia Unveils Promising DA-1241 Trial Results - TipRanks
Asian shares get a lift from plans for China-US trade talks, Beijing stimulus moves - WFMZ.com
MetaVia Presents Data on DA-1241, a GPR119 Agonist, Demonstrating Both Hepatoprotective and Glucose-Regulating Effects in Patients with Presumed MASH, at the EASL Congress 2025 - PR Newswire
Metavia Presents Data On DA-1241, A GPR119 Agonist, Demonstrating Both Hepatoprotective And Glucose-Regulating Effects In Patients With Presumed MASH, At The EASL Congress 2025 - MENAFN.com
Senate confirms Bisignano to lead Social Security Administration as agency faces DOGE overhaul - WFMZ.com
Trump’s meme coin business racks up fees as buyers jump at the chance for access to the president - WFMZ.com
MetaVia Inc expected to post a loss of 60 cents a shareEarnings Preview - TradingView
MetaVia’s Promising Clinical Trial Results and Future Prospects Drive Buy Rating - TipRanks
MetaVia’s DA-1241 shows promise in Phase 2a MASH trial By Investing.com - Investing.com South Africa
Copper Miner Rallies as Takeover Buzz Sparks Investor Optimism - The Globe and Mail
MetaVia Announces Late-Breaking Poster Presentation on DA-1241 at the EASL Congress 2025 - Eastern Progress
MetaVia’s DA-1241 shows promise in Phase 2a MASH trial - Investing.com
MetaVia’s ‘Safe’ Obesity Drug Resonates With Analysts, But Not Investors - insights.citeline.com
MetaVia reports promising obesity drug trial results By Investing.com - Investing.com South Africa
How will MetaVia Inc’s (MTVA) earnings compare to estimates this quarter? - uspostnews.com
RIVN’s Q2 earnings predictions: What the experts say - uspostnews.com
Can Newell Brands Inc (NWL) meet market expectations this quarter? - uspostnews.com
MetaVia Reports Additional Positive Top-Line Results From the MAD Part 2 of Its Phase 1 Study of DA-1726, a Novel 3:1 Ratio GLP-1 and Glucagon Dual Receptor Agonist to Treat Obesity, Further Demonstrating Its Best-In-Class Potential - The Malaysian Reserve
MetaVia (MTVA) Advances DA-1726 in Obesity Treatment with Promis - GuruFocus
MetaVia Reports Positive Phase 1 Trial Results - TipRanks
1.91%
1.17%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):